China’s CMAB Biopharma captures $34M in series B funding to upgrade facilities

Suzhou, China
The company said it will use the funds to upgrade its plant in the Suzhou BioBay Park in China. (Christian Gänshirt/CC BY-SA 4.0)

CMAB Biopharma, a China-based CDMO, snagged $34 million in series B financing the company said will be used to upgrade and expand its manufacturing plant.

The company, which specializes in the development and manufacturing of biologics products, said it will use the funds to upgrade its plant in the Suzhou BioBay Park in China. 

The funding round was led by CD Capital, with joint participation by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“We aim to bring our client expertise and knowledge to efficiently advance products from concept into the clinic,” Qibin Liang, CMAB’s president, said in a statement. “This financing furthers our vision to become a fully integrated CDMO platform providing clinical and commercial production services to the Chinese domestic and the international biologics markets.”

The company said its manufacturing facility will be able to generate preclinical and early-stage clinical (phase 1/2) products using manufacturing that follows global GMP standards.


Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.